Cetrorelix Acetate for Healthy Subjects (HS)

Phase-Based Progress Estimates
Healthy Subjects (HS)
Cetrorelix Acetate - Drug
18 - 65
What conditions do you have?

Study Summary

This trial will look at the effects of testosterone on the autonomic nervous system (which controls involuntary body functions like heart rate) and blood vessels in men.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone

Day 7
Endothelial function
Forearm blood flow
Muscle sympathetic nerve activity
Sex hormones
Skeletal muscle microvascular blood flow

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

GnRH antagonist alone
1 of 2
GnRH antagonist + Testosterone add-back
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Cetrorelix Acetate · No Placebo Group · N/A

GnRH antagonist alone
Experimental Group · 1 Intervention: Cetrorelix Acetate · Intervention Types: Drug
GnRH antagonist + Testosterone add-backExperimental Group · 2 Interventions: Cetrorelix Acetate, Testosterone gel · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: after 7 days gnrh antagonist alone and 7 days gnrh antagonist + testosterone

Who is running the clinical trial?

Western University, CanadaLead Sponsor
191 Previous Clinical Trials
36,126 Total Patients Enrolled
3 Trials studying Healthy Subjects (HS)
330 Patients Enrolled for Healthy Subjects (HS)
Joel K Shoemaker, Ph.D.Principal InvestigatorUniversity of Western Ontario, Canada

Eligibility Criteria

Age 18 - 65 · Male Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 6566.7%
What site did they apply to?
the University of Western Ontario100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%